A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term protection, simplifying adherence, and expanding access to at-risk populations., Hea ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency virus (HIV), a discovery that brings medical experts one step closer to a cure ...

Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...

Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir.

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

In the general population, frailty is an aging-related risk factor for poor outcomes; individuals experiencing frailty face ...

The man’s case didn’t give rise to any widespread variant, but it gave Gupta, with his HIV evolution background, the idea ...

Chronic kidney disease (CKD) affects approximately 850 million people worldwide and, if left undiagnosed, can progress to ...

Understanding how ... A Chain Reaction: HIV Vaccines Can Lead to Antibodies Against Antibodies Jan. 17, 2025 — Many vaccines work by introducing a protein to the body that resembles part of a virus.